DISRUPT PAD II
By The Numbers
*Guidewire induced through recanalization of a CTO
Minimize trauma to soft tissue by safely selecting and fracturing intimal and medial calcium
Optimize outcomes while reducing complications and cost escalation
Simple and intuitive system that makes complex calcified procedures more predictable
But, right now we're in the early phases of the R&D program. In the meantime, don't miss the IVL application that heart teams are embracing already — maintaining transfemoral TAVR access through heavily calcified iliacs by using IVL.
Too bad our coronary technology is not yet approved in the United States. Good news is that we have initiated our U.S. FDA IDE study. Learn more about the Disrupt CAD III study on our clinical research portion of the website.
IT’S TIME TO
COUNTDOWN TO CAD III PRESENTATION
Caution: Investigational device. Limited by Federal (U.S.) law to investigational use.